McKesson will incorporate Proventys’ risk prediction capabilities into the McKesson core clinical decision support solutions, as part of a newly formed strategic relationship.

The Durham, N.C.-based Proventys translates predictive data from traditional and emerging diagnostic tests, including genomics, proteomics and metabolomics, into clinical decision support solutions, according to McKesson.

“The work we will do together will help to define a new healthcare delivery system focused on supporting the next generation of medicine,” said Pamela Pure, president of McKesson Technology Solutions. “Physicians already struggle to make effective, informed, efficient care decisions based on the numerous patient variables they must consider when providing treatment. As those variables increase exponentially over the next few years, physicians will require increasingly sophisticated clinical decision support tools to help them.”